Search results for "Coagulant"

showing 10 items of 342 documents

Predictive value of the Kuijer score for bleeding and other adverse in-hospital events in patients with venous thromboembolism

2021

Venous thromboembolism (VTE) constitute a major global burden of disease. Current international guidelines recommend treatment with anticoagulant therapy after VTE for a duration of at least 3 months. Since anticoagulation also imposes an increased risk for bleeding events, the individual risk has to be evaluated to determine adequate treatment plans.The nationwide German inpatient sample of the years 2005-2017 was used for this analysis. Hospitalized VTE patients were stratified according to Kuijer risk class and the performance of the Kuijer score was evaluated to predict adverse in-hospital events.Overall, 1,204,895 VTE patients were treated between 2005 and 2017 in Germany and were incl…

medicine.medical_specialtyHemorrhage030204 cardiovascular system & hematologyThrombophlebitis03 medical and health sciences0302 clinical medicineRisk FactorsInterquartile rangeGermanyInternal medicinemedicineHumansIn patientHospital Mortality030212 general & internal medicinebusiness.industryAnticoagulantsVenous ThromboembolismOdds ratiomedicine.diseaseHospitalsConfidence intervalPulmonary embolismVenous thrombosisCardiology and Cardiovascular MedicinebusinessVenous thromboembolismInternational Journal of Cardiology
researchProduct

Atrial fibrillation in high-risk patients with ischaemic stroke – Authors' reply

2017

medicine.medical_specialtyHigh risk patientsbusiness.industryMEDLINEAnticoagulantsAtrial fibrillation030204 cardiovascular system & hematologymedicine.diseaseStroke03 medical and health sciences0302 clinical medicineText miningRisk FactorsInternal medicineAtrial FibrillationIschaemic strokeCardiologyHumansMedicineNeurology (clinical)businessStroke030217 neurology & neurosurgeryThe Lancet Neurology
researchProduct

Chronic thromboembolic pulmonary hypertension from the perspective of patients with pulmonary embolism

2018

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but feared long-term complication of acute pulmonary embolism (PE), although CTEPH may occur in patients with no history of symptomatic venous thromboembolism. It represents the most severe presentation of the so-called 'post-PE syndrome', a phenomenon of permanent functional limitations after PE caused by deconditioning after PE or ventilatory or circulatory impairment as a result of unresolved pulmonary artery thrombi. Because the post-PE syndrome may occur in up to 50% of PE survivors, and CTEPH tends to have an insidious and non-specific clinical presentation, CTEPH is often not diagnosed or diagnosed after a very long dela…

medicine.medical_specialtyHypertension Pulmonarymedicine.medical_treatmentHemodynamicsEndarterectomyPulmonary Artery030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciences0302 clinical medicineRisk FactorsAngioplastyInternal medicinemedicine.arterymedicineHumansArterial PressureBlood CoagulationAntihypertensive Agentsbusiness.industryAnticoagulantsHematologymedicine.diseasePulmonary hypertensionPulmonary embolismTreatment Outcomemedicine.anatomical_structure030228 respiratory systemChronic DiseaseCirculatory systemPulmonary arteryCardiologyVascular resistancePulmonary EmbolismbusinessComplicationAngioplasty BalloonJournal of Thrombosis and Haemostasis
researchProduct

Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials.

2021

Abstract Aims  The aim of this study was to systematically assess the effects of antiplatelets on clinical outcomes in patients with atrial fibrillation (AF), treated and not-treated with oral anticoagulation. Methods and results  We searched MEDLINE, Embase, and CENTRAL from inception until September 2020. From 5446 citations, we selected randomized trials allocating patients with AF to antiplatelet therapy vs. control. We applied random-effects models for meta-analysis and assessed potential effect modification with background anticoagulation use. Eighteen trials including 21 518 participants met our prespecified eligibility criteria. In 10 studies without background anticoagulation, anti…

medicine.medical_specialtyMEDLINEMyocardial InfarctionHemorrhage030204 cardiovascular system & hematologylaw.inventionBrain Ischemia03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineAtrial FibrillationMedicineHumansPharmacology (medical)030212 general & internal medicineMyocardial infarctionStrokeRandomized Controlled Trials as TopicAspirinbusiness.industryAnticoagulantsAtrial fibrillationmedicine.diseaseConfidence interval3. Good healthStrokeRelative riskCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitorsmedicine.drugEuropean heart journal. Cardiovascular pharmacotherapy
researchProduct

Evaluating the effectiveness and risks of oral anticoagulant treatments in multimorbid frail older subjects with atrial fibrillation using the multid…

2018

Background: Previous studies suggested that a different risk of mortality may influence the oral anticoagulant prescription in older patients with atrial fibrillation (AF). Recently, the Multidimensional Prognostic Index (MPI) demonstrated a high grade of accuracy, calibration and feasibility to predict mortality in hospitalized and community-dwelling older people. Prognostic information, as calculated by the MPI, however, is not included in the decision algorithm of treatments in older patients with AF Purpose: The aim of this international multicenter prospective observational study was to evaluate whether a different prognostic profile, as determined by the MPI, is associated with differ…

medicine.medical_specialtyMuldimensional Prognostic IndexPopulationlaw.invention03 medical and health sciencesElderly0302 clinical medicineRandomized controlled triallawInternal medicineAtrial FibrillationmedicineRisk of mortality030212 general & internal medicineMedical prescriptioneducationAnticoagulants; Atrial Fibrillation; Elderly; Frailty; Muldimensional Prognostic Indexeducation.field_of_studyFrailtybusiness.industryAnticoagulantWarfarinAnticoagulantsAtrial fibrillationmedicine.diseaseRelative riskObservational studyGeriatrics and GerontologybusinessGerontology030217 neurology & neurosurgerymedicine.drugEuropean Geriatric Medicine
researchProduct

Risk Factors Affect Long-Term Compliance to Coumadin Treatment (Self-Reporting)

2017

Abstract Low compliance to a prescribed Coumadin treatment can result in negative health outcomes. In this study we aimed to evaluate risk factors affecting patient compliance to Coumadin. For this purpose, two study phases were performed: Phase 1: a retrospective eight-year follow-up of databases from health care services; and Phase 2: a cross-sectional study with telephone interviews. A Total Compliance Index was constructed using the number of Coumadin purchases (40%), international standardised ratio (INR) tests (40%), and average INR values (20%). Multiple models for the Total Compliance Index were constructed using socio-demographic, treatment-related, and health care utilisation vari…

medicine.medical_specialtyMultidisciplinaryGeneral interestcompliance to treatmentSciencetotal compliance indexQAffect (psychology)Compliance (psychology)Term (time)international standardised ratio (inr)anti-coagulant treatmentmedicinecoumadinIntensive care medicineProceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.
researchProduct

Stability of Ascorbic Acid in Several Blood Collecting Procedures

2003

Purpose: There is good evidence that ascorbic acid (AA) status influences the onset of post-operative complications in intensive care patients. Light and room temperature cause the spontaneous oxidation of AA. Therefore, the stability of AA during modified sample preparation was investigated. Design: Prospective, single centre study. Methods: The AA plasma concentration was analysed in arterial and venous blood with added ethylene-diamine-tetra-acetic acid (EDTA) from 165 subjects. In addition, EDTA or heparin was added as an anticoagulant in venous blood of 79 subjects. Analyses were carried out using high performance liquid chromatography with ultraviolet detection. Results: In samples of…

medicine.medical_specialtyNutrition and DieteticsChromatographymedicine.drug_classChemistryAnticoagulantPublic Health Environmental and Occupational HealthMedicine (miscellaneous)HeparinVenous bloodAscorbic acidHigh-performance liquid chromatographySurgerySpecimen collectionIntensive caremedicineSample preparationFood Sciencemedicine.drugJournal of Nutritional & Environmental Medicine
researchProduct

Dabigatran: A new oral anticoagulant. Guidelines to follow in oral surgery procedures. A systematic review of the literature.

2015

Background Dabigatran is a newly commercialized drug that is replacing other anticoagulants in the prevention of venous thromboembolism, stroke and systemic arterial valve embolism. It acts directly on thrombin presenting in a dynamic and predictable way, which does not require monitoring these patients. Therefore, we consider the need to assess whether their use increases the risk of bleeding involved before any dental treatment. Material and Methods We performed a systematic review with a bibliographic search in PubMed/Medline along with the Cochrane Library. We excluded articles dealing with all anticoagulants other than dabigatran, and works about surgical treatments in anatomical locat…

medicine.medical_specialtyOral Surgical ProceduresPsychological interventionMEDLINEAdministration OralReviewCochrane LibraryPostoperative Hemorrhagelaw.inventionDabigatran03 medical and health sciences0302 clinical medicineRandomized controlled triallawMedicineHumansIntensive care medicineGeneral DentistryStrokebusiness.industryAnticoagulants030206 dentistry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseMedically compromised patients in DentistrySurgeryDabigatranClinical trialOtorhinolaryngologyEmbolism030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASSurgerybusinessmedicine.drugMedicina oral, patologia oral y cirugia bucal
researchProduct

Extractions without eliminating anticoagulant treatment: A literature review

2010

To establish whether there is a high enough risk of bleeding in patients who take oral anticoagulants, such that it would justify not using oral anticoagulants when performing a dental extraction, as well as if the reason for and anatomical location of the extraction increases such risk. Study We performed a bibliographic search in order to carry out a meta-analytic study using descriptive statistics. We compiled a sample of 1194 patients from the articles selected. Of these patients, a total of 2392 simple, serial surgical extractions were performed; none of the patients interrupted their anticoagulant treatment with warfarin sodium. Of the sample, 83 patients presented a certain degree of…

medicine.medical_specialtyPeriodontal pathologybusiness.industryContraindicationsmedicine.medical_treatmentIncidence (epidemiology)AnticoagulantsDentistrySoft tissue:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseSurgeryOtorhinolaryngologyDental extractionAnticoagulant therapyMaxillaHemostasisTooth ExtractionUNESCO::CIENCIAS MÉDICASHumansMedicineSurgeryPericoronitisbusinessGeneral DentistryMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group 'Hypertension Arrhythmias an…

2012

Hypertension is the most common cardiovascular disorder and atrial fibrillation is the most common clinically significant arrhythmia. Both these conditions frequently coexist and their prevalence increases rapidly with aging. There are different risk factors and clinical conditions predisposing to the development of atrial fibrillation, but due its high prevalence, hypertension is still the main risk factor for the development of atrial fibrillation. Several pathophysiologic mechanisms (such as structural changes, neurohormonal activation, fibrosis, atherosclerosis, etc.) have been advocated to explain the onset of atrial fibrillation. The presence of atrial fibrillation per se increases th…

medicine.medical_specialtyPhysiologymacromolecular substancesFibrosisRisk FactorsCardiovascular DisorderInternal medicineThromboembolismAtrial FibrillationInternal MedicinemedicineHumanscardiovascular diseasesRisk factorStrokeSocieties Medicalbusiness.industryWarfarinAtrial fibrillationHypertension atrial fibrillation anticoagulants antihypertensive treatmentMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREmedicine.diseaseThrombosisEuropeBlood pressureHypertensionCardiologyCardiology and Cardiovascular Medicinebusinessmedicine.drugJournal of hypertension
researchProduct